Allogeneic Mesenchymal Stem Cell Therapy with Laromestrocel in Mild Alzheimer’s Disease: A Randomized Controlled Phase IIa Trial

Scientists conducted a randomized, double-blind, placebo-controlled, parallel-group Phase IIa clinical trial that tested the safety and efficacy of laromestrocel, a bone-marrow-derived, allogeneic mesenchymal stem-cell therapy, in slowing Alzheimer’s disease clinical progression, atrophy and neuroinflammation.